Centauri Therapeutics Strengthens Senior Leadership Team With Three Key Appointments
Dr Jennifer Schneider appointed CEO, Dr Helen Bright joins as VP of Research & Development, and Professor David Roblin will Chair the Board of Directors Senior appointments support acceleration of novel immunotherapies to treat infectious disease, leveraging the Alphamer platform Team expansion follows recent £24m investment from Boehringer Ingelheim Venture Fund, Evotec SE and Novo … [Read more…]
